Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Isaac Manke, Ph.D. Dr. Manke has served as the chairman and a member of our board of directors since March 2026. Dr. Manke has more than 20 years of experience investing in, evaluating, financing, and advising biotechnology companies across public and private markets, including as a venture capitalist, equity research analyst, public company director, and life sciences strategist. Dr. Manke has served as Senior Vice President, Strategy and Business Development of OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”) since February 2026 and as a member of the board of directors since March 2021. From April 2020 to July 2025, Dr. Manke served as General Partner at Acorn BioVentures, where he focused on investments in public and private biotechnology companies. From 2009 to 2019, Dr. Manke served as a Partner at New Leaf Venture Partners. Earlier in his career, Dr.
This record is keyed to SEC CIK 0001622769 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row.